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Abstract The binding pro¢le of [3H]BHDP ([3H]N-benzyl-NP-
(2-hydroxy-3,4-dimethoxybenzyl)-piperazine) was evaluated.
[3H]BHDP labelled a single class of binding sites with high
a⁄nity (Kd = 2^3 nM) in rat liver mitochondria and synaptic
membranes. The pharmacological characterization of these
sites using c reference compounds revealed that these sites are
c receptors and, more particularly, c1 receptors. Indeed, BHDP
inhibited [3H]pentazocine binding, a marker for c1 receptors,
with high a⁄nity in a competitive manner. BHDP is selective
for c1 receptors since it did not show any relevant a⁄nity for
most of the other receptors, ion channels or transporters tested.
Moreover, in an in vitro model of cellular hypoxia, BHDP
prevented the fall in adenosine triphosphate (ATP) levels caused
by 24 h hypoxia in cultured astrocytes. Taken together, these
results demonstrate that [3H]BHDP is a potent and selective
ligand for c1 receptors showing cytoprotective e¡ects in astro-
cytes.
1 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Key words: c Receptor; Liver mitochondrion; Synaptosome;
Binding; Hypoxia; Astrocyte
1. Introduction
It is now well established that c receptors are distinct enti-
ties and di¡er from any other known receptor [1]. These re-
ceptors are expressed in various areas of the brain and in
peripheral organs including liver, testis, kidney, spleen and
intestine. c Receptors have been classi¢ed at least into two
subtypes, termed c1 and c2, which were distinguished by bio-
chemical and pharmacological studies [2]. The ¢rst one shows
high a⁄nity for benzomorphans, a stereoselectivity for the
(+)-isomers, and is usually labelled with the radioligand
[3H](+)-pentazocine [3,4] whereas the second exhibits a lower
a⁄nity for (+)-pentazocine and a reverse stereoselectivity.
Usually c2 binding sites are probed with 1,3-di(2-tolyl)guani-
dine (DTG) which binds to both subtypes 1 and 2 in roughly
equal amounts.
The pattern of distribution of these receptors among sub-
cellular fractions of di¡erent organs indicates that these re-
ceptors are highly concentrated and mainly located on micro-
somal and plasma membranes [3,5]. However, recent studies
also demonstrated the presence of c receptors in rat brain and
liver mitochondrial membranes [6,7]. These receptors were
located on the outer mitochondrial membrane but their phar-
macological signi¢cance and their role on mitochondrial func-
tion remain unknown. In order to study the role of these
receptors we search for a selective ligand devoid of mitochon-
drial toxicity. Indeed, usual ligands such as haloperidol or
pentazocine, were shown to alter mitochondrial respiration
[8] which hampered their use.
We identi¢ed among a series of piperazine derivatives syn-
thesized by two of us (M.F. Boussard, M. Wierzbicki) a com-
pound, N-benzyl-NP-(2-hydroxy-3,4-dimethoxybenzyl)-pipera-
zine (BHDP) (Fig. 1), which exhibited several properties
indicating that it could be a c ligand. This drug is structurally
related to N-substituted 4-benzylpiperidines, such as ifenpro-
dil and eliprodil, which exhibit high a⁄nity for c1 receptors
[9,10], and its chemical structure is similar to that of SA4503
which has recently been shown to be a potent and selective c1
receptor agonist [11]. In addition, BHDP was shown to inhibit
the binding of [3H]pentazocine, a prototype ligand for c1
receptors. This prompted us to analyze the binding properties
of BHDP. In the present study, we characterized the binding
properties of [3H]BHDP to c receptors ¢rst, in mitochondria
puri¢ed from rat liver, and then in rat brain synaptosomes,
and compared these properties with those of typical c recep-
tor ligands. In addition, BHDP was tested for its ability to
protect cultured astrocytes against hypoxia-induced adenosine
triphosphate (ATP) depletion.
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2. Materials and methods
2.1. Drugs
[3H]BHDP (84 Ci/mmol) was obtained from Amersham. [3H](+)-
pentazocine and [3H]DTG were purchased from New England Nu-
clear (Paris, France). NE-100 was synthesized according to [12]. Other
drugs and chemicals were obtained from Sigma (St Quentin Fallavier,
France) or Merck (Nogent-sur-Marne, France) and were of the high-
est purity available.
2.2. Preparation of synaptosomal membranes and puri¢ed rat liver
mitochondria
Puri¢ed rat liver mitochondria and synaptosomal membranes were
obtained as previously described [7]. Protein contents were determined
by the method of Lowry et al. [13].
2.3. Receptor binding assay
Binding of [3H]BHDP to rat liver and brain synaptosomes was
measured as follows: mitochondria or synaptic membranes (0.5 mg/
ml) were incubated with [3H]BHDP in 250 Wl of 50 mM Tris^HCl
bu¡er (pH=8) for 150 min at 25‡C. For saturation experiments the
range of concentrations of [3H]BHDP was 0.1^20 nM. For inhibition
experiments 0.5^1 nM [3H]BHDP was incubated in the absence or in
the presence of increasing concentrations (15) of the competing drug.
Non-speci¢c binding was de¢ned using 1 WM haloperidol. Inhibition
of [3H](+)-pentazocine and [3H]DTG binding to rat brain membranes
was measured as previously described [7,11]. Brie£y, each assay tube
contained 2 nM [3H](+)-pentazocine or 5 nM [3H]DTG (in the pres-
ence of 0.4 WM (T )pentazocine to mask c1 binding), brain mem-
branes (1 mg/ml) and various concentrations of BHDP in a ¢nal
volume of 500 Wl. Incubations were carried out at 37‡C for 150 min
in the [3H](+)-pentazocine assay and at 25‡C for 90 min in the
[3H]DTG assay.
For competition binding studies performed at other receptor types,
assay conditions are summarized in Table 2.
Binding was stopped by the addition of ice-cold binding bu¡er, and
bound and free ligands were separated by rapid ¢ltration through
Whatman GF/B glass ¢ber ¢lters (presoaked in 0.1% polyethyleni-
mine). Each ¢lter was washed twice with an additional 5 ml of ice-
cold Tris bu¡er (50 mM) and counted in a liquid scintillation counter
Packard 1600 TR with an e⁄ciency of 45%.
2.4. Astrocytes in tissue culture
Astrocyte cultures were obtained from neonate rats using a tech-
nique described by Booher and Sensenbrenner [14]. After the me-
ninges had been cleaned o¡, the brain tissue was forced gently
through a nylon sieve (180 Wm). Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (Hyclone, USA),
2 mM glutamine and 50 Wg/ml of gentamicin was used for the disso-
ciation of cerebral tissue and development of astrocytes. Cultures were
used for 3 weeks after preparation. The oxygen-free culture medium
(DMEM) was added and di¡erent concentrations of drug were then
added. Hypoxia was carried out in an anaerobic chamber (98% N2,
2% O2) for 24 h. ATP was extracted and the ATP concentration,
expressed in pmol of ATP/mg of cell proteins, was measured by a
luciferin-luciferase method using a Sigma kit. The decrease in ATP
in the cells (expressed as a percentage) after 24 h hypoxia gave a
measurement of the severity of the insult. As demonstrated by the
LDH test (Sigma), no cell lysis was observed after the 24 h experi-
ments (data not shown).
2.5. Data analysis
Equilibrium (Kd (dissociation constant) and Bmax values (maximal
density of binding sites)), and inhibition (IC50) binding parameters
were calculated by means of a non-linear regression method using a
commercially available software (Micropharm, INSERM 1990; [15])
by modeling the data according to Hill equations as described previ-
ously [16].
All data are presented as the meanTS.E.M. of three or more in-
dividual experiments. They were compared by one-way analysis of
variance (ANOVA); a statistically signi¢cant di¡erence was accepted
if P6 0.05.
3. Results
3.1. Characterization of [3H]BHDP binding to liver
mitochondria
Binding of low concentrations of [3H]BHDP to liver mito-
Fig. 1. Chemical structure of BHDP. *Labelling position.
Fig. 2. Kinetics of [3H]BHDP binding to rat liver mitochondria and
e¡ect of pH. Association experiment (A): Liver mitochondria (0.5
mg/ml) were incubated with 0.5 nM [3H]BHDP at 25‡C. Dissocia-
tion experiment (B): After equilibrium was reached, dissociation
was induced by dilution and speci¢c binding monitored for 120
min. Data shown are typical experiments plotted as fractions of the
maximal binding value ([3H]BHDP bound=1). E¡ect of pH (C):
Liver mitochondria (0.5 mg/ml) were incubated with 0.5 nM
[3H]BHDP at 25‡C. Each point represents the meanTS.E.M. of
three experiments performed in triplicate. Non-speci¢c binding was
de¢ned in the presence of 1 WM haloperidol.
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chondria is saturable and time dependent, reaching equilibri-
um after 120 min of incubation at 25‡C (Fig. 2A). The same
pattern was obtained with broken mitochondria, i.e. when
they were subjected to hypoosmotic shock and sonication,
indicating that the radioligand did not accumulate within mi-
tochondria without binding. After equilibrium was reached,
dilution of the suspension (1/100) induced a slow dissociation
of [3H]BHDP from its binding sites, demonstrating that the
binding was reversible (Fig. 2B). BHDP binding was also pH
dependent. Maximum binding occurred at pH=8, so all ex-
periments were performed at this pH (Fig. 2C).
Equilibrium binding experiments with [3H]BHDP concen-
trations ranging from 0.1 to 30 nM revealed that the speci¢c
binding was saturable. The non-linear regression analysis re-
vealed that [3H]BHDP recognized a single class of binding
sites (nH = 1) with mean Kd and Bmax values of 3.18T 0.55
nM and 2.17T 0.17 pmol/mg, respectively. The linear Scatch-
ard plot con¢rmed this analysis of the data. A representative
binding curve is shown on Fig. 3A.
In order to verify that the [3H]BHDP binding sites in liver
mitochondria correspond to a c binding site, inhibitory e¡ects
of several reference c ligands on [3H]BHDP binding were
studied (Table 1).
BHDP and the antipsychotic dopamine receptor antagonist
haloperidol, which is commonly used as a c receptor ligand,
were the most potent inhibitors of [3H]BHDP binding. NE-
100, ( T )pentazocine, ifenprodil, carbetapentane and 3-(3-hy-
droxyphenyl)-N-(1-propyl)piperidine (3-PPP) showed good af-
¢nity for these sites (IC506 100 nM), whereas progesterone
and dextrometorphan were less active. Rimcazole was the
lowest inhibitor of the well-identi¢ed c receptor ligands tested
with an IC50 value of 1550 nM. It should be noted that all
these compounds, except ( T )pentazocine, displaced
[3H]BHDP binding with a Hill coe⁄cient (nH) value close to
unity, additional evidence for the presence of a single popu-
lation of binding sites. The result obtained with ( T )pentazo-
cine (nH6 1) was probably due to the use of the racemic form
of the drug as the two enantiomers have been shown to have
di¡erent a⁄nities for c receptors [2,17].
3.2. Characterization of [3H]BHDP binding to rat brain
synaptosomal membranes
c Receptors are highly concentrated in brain and most of
the studies designed to analyze the binding properties of ra-
diolabelled c ligands have been performed on rat or guinea
pig brain membranes. In order to con¢rm the binding of
Fig. 3. Representative equilibrium binding curve of [3H]BHDP binding to liver mitochondria (A) and brain membranes (B). Concentration of
[3H]BHDP (0.1^30 nM) was incubated with liver mitochondria or brain synaptosomes (0.5 mg/ml) for 150 min at 25‡C and non-speci¢c bind-
ing was de¢ned using 1 WM haloperidol. Equilibrium parameters were estimated by a non-linear regression analysis. In these particular experi-
ments, Kd and Bmax values were 2.15 nM and 2.5 pmol/mg protein and 1.59 nM and 0.46 pmol/mg protein in liver mitochondria and brain
membranes, respectively. Inset: Scatchard plot.
Table 1
Inhibition of [3H]BHDP binding by various c reference ligands
c Ligands Liver mitochondria Brain synaptosomes
IC50 (nM) nH IC50 (nM) nH
Haloperidol 7.93T 1.25 0.95T 0.02 8.96T 1.09 0.95T 0.22
( T )Pentazocine 40.97T 1.76 0.68T 0.07a 38.5T 6.37 0.75T 0.07a
BHDP 5.69T 0.82 0.93T 0.08 3.64T 0.76 0.95T 0.21
NE-100 10.1T 2.50 0.85T 0.17 9.62T 2.10 0.83T 0.19
DTG 115T 13.5 1.14T 0.07 94.3T 32.4 1.13T 0.07
Ifenprodil 19.3T 5.79 0.97T 0.12 8.50T 1.63 0.91T 0.14
Carbetapentane 50.6T 6.21 1.30T 0.20 25.5T 2.95 1.13T 0.20
( T )3-PPP 93.3T 8.11 0.93T 0.55 97T 11 0.94T 0.08
Rimcazole 1550T 144 1.12T 0.05 1733T 285 1.02T 0.09
Dextrometorphan 476T 4.88 0.97T 0.05 580T 63.8 0.98T 0.07
Progesterone 188T 31.6 0.94T 0.04 121T 9.75 0.62T 0.22
DHEA 2450T 86.6 1.05T 0.09 1800T 115 0.73T 0.22
Data shown are the meanTS.E.M. of three to four experiments. [3H]BHDP concentration was 0.5^1 nM. IC50 values were estimated by a non-
linear regression analysis by a Hill model. A Hill coe⁄cient (nH) value equal to 1 indicates that the interaction is competitive. All drugs dis-
placed 100% of [3H]BHDP speci¢c binding.
DHEA, dehydroepiandrosterone.
aStatistically smaller than 1.
FEBS 27660 24-9-03
A. Klouz et al./FEBS Letters 553 (2003) 157^162 159
[3H]BHDP to c receptors, we investigated the binding proper-
ties of [3H]BHDP in rat brain. Here again, [3H]BHDP binding
was saturable and labelled a single class of sites (Kd =
2.08T 0.28 nM, Bmax = 0.42 T 0.11 pmol/mg) as suggested by
the linear Scatchard plot (Fig. 3B). Pharmacological charac-
terization using reference c compounds con¢rmed the c re-
ceptor pro¢le of the radioligand (Table 1). The rank order of
potency was identical to that observed in liver mitochondria,
showing a strong correlation (r=0.988; P6 0.0001; Fig. 4).
In addition, BHDP was able to displace the speci¢c binding of
[3H](+)-pentazocine and [3H]DTG (Fig. 5) which are now
commonly used to speci¢cally label c1 and c2 receptors, re-
spectively.
BHDP had a high a⁄nity for [3H](+)-pentazocine binding
sites in rat brain synaptosomal membranes with an IC50 value
of 6.62T 1.79 nM. It is similar to the a⁄nity values obtained
with [3H]BHDP in saturation and inhibition experiments. On
the other hand, BHDP has a lower a⁄nity for the c2 receptor
Fig. 4. Relationship between the a⁄nity of c reference compounds
for [3H]BHDP binding to liver mitochondria and brain synapto-
somes. Plotted are IC50 values listed in Table 1. Regression line was
obtained by least squares ¢t analysis of the data points.
Fig. 5. Inhibition of [3H]pentazocine and [3H]DTG binding to rat
brain synaptosomes (0.5 mg/ml) by increasing concentrations of
BHDP. Data shown are from typical experiments and are plotted
as fractions of the control [3H]pentazocine or [3H]DTG binding
values (in the absence of BHDP [3H]radioligand bound=1).
[3H]pentazocine and [3H]DTG concentrations were 2 and 5 nM, re-
spectively.
Table 2
Radioligand binding conditions and e¡ects of BHDP on several receptors, transporters and ionic channels
Target Radioligand (nM) Tissue Non-speci¢c (WM) Incubation BHDP (IC50, WM)
Receptors
Adenosine A1 [3H]DPCPX (1) CHO cells DPCPX (1) 60 min/22‡C s 10
Adenosine A2 [3H]CGS 21680 (6) rat striatum NECA (100) 90 min/22‡C s 10
K1-adrenergic [3H]prazosin (0.25) rat cortex prazosin (0.5) 60 min/22‡C s 10
K2A-adrenergic [3H]RX821002 (0.8) CHO cells phentolamine (10) 45 min/25‡C 8.5
K2B-adrenergic [3H]RX821002 (1) CHO cells phentolamine (10) 45 min/25‡C 4.0
K2C-adrenergic [3H]RX821002 (2) CHO cells phentolamine (10) 45 min/25‡C 1.8
L-adrenergic [3H]CGP 12177 (0.5) rat cortex isoproterenol (100) 60 min/25‡C s 10
Dopaminergic D1 [3H]SCH 23390 (0.3) rat striatum SCH 23390 (10) 45 min/22‡C s 10
Dopaminergic D2 [3H]YM-09151-2 (0.1) rat striatum (+)-butaclamol (10) 60 min/22‡C W10
Histamine H1 [3H]pyrilamine (0.5) g.p. cerebellum triprolidine (100) 10 min/22‡C s 10
Histamine H2 [125I]APT (0.1) g.p. striatum tiotidine (10) 150 min/22‡C s 10
5-HT1A [3H]8-OH-DPAT (0.4) rat hippocampus 5-HT (10) 15 min/37‡C 1.6
5-HT2A [3H]ketanserin (0.5) rat cortex ketanserine (1) 15 min/37‡C W10
5-HT2B [3H]5-HT (0.4) Cos-7 cells 5-HT (10) 120 min/4‡C 0.19
5-HT2C [3H]mesulergine (1) CHO cells mianserin (10) 30 min/37‡C s 10
5-HT3 [3H]BRL 43694 (1) N1E-115 cells METO (100) 180 min/4‡C s 10
Cannabinoides [3H]WIN 55212-2 (0.5) rat cerebellum WIN 55212-2 (1) 90 min/37‡C s 10
Endothelin A [125I]endothelin-1 (0.01) CHO cells endothelin-1 (0.1) 120 min/37‡C s 10
GABA [3H]GABA (10) rat cortex GABA (1000) 20 min/22‡C s 10
AMPA [3H]AMPA (5) rat cortex L-GLU (1000) 60 min/4‡C s 10
NMDA [3H]CGP 39653 (5) rat cortex L-GLU (100) 60 min/4‡C s 10
Muscarinic [3H]QNB (0.05) rat cortex atropine (1) 120 min/22‡C s 10
Nicotinic [3H]cytisine (1.5) rat cortex nicotine (10) 75 min/4‡C s 10
Neuropeptide Y [3H]neuropeptide Y (0.5) rat cortex neuropeptide Y (1) 90 min/22‡C s 10
Opioids [3H]naloxone (1) rat cortex naloxone (1) 40 min/22‡C s 10
TXA2/PGH2 [3H]SQ 29,548 (5) human platelets U44069 (0.05) 30 min/22‡C s 10
Amine uptake sites
Dopamine [3H]BTCP (0.5) rat striatum BTCP (10 WM) 90 min/4‡C W10
5-HT [3H]paroxetine (0.05) rat cortex serotonine (100) 15 min/37‡C s 10
Noradrenaline [3H]nisoxetine (1) rat cortex desipramine (1) 240 min/4‡C s 10
Ion channels
Ca2þ, L type [3H]diltiazem (5) rat cortex diltiazem (10) 120 min/22‡C s 10
Kþ, ATP sensitive [3H]glibenclamide (0.1) rat cortex glibenclamide (1) 60 min/22‡C s 10
Kþ, volt. dependent [125I]CHBT (0.05) rat cortex CHBT (0.01) 15 min/22‡C) s 10
g.p., guinea pig; METO, metoclopramide; L-GLU, L-glutamate; CHBT, charybdotoxin.
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subtype with an IC50 value of 713T 95 nM. These data rein-
forced our hypothesis that BHDP preferentially labelled c1
receptors.
3.3. Selectivity of BHDP for c receptors
The a⁄nity of BHDP for a number of receptors, ionic
channels or amine transporters was studied. Binding assays
were performed according to the references listed in Table 2.
BHDP showed low a⁄nity (IC50v 10 WM) for most of the
receptors examined (Table 2). Exceptions were 5-HT1A and
5-HT2B receptors, exhibiting an IC50 value of 1.6 and
0.19 WM, respectively. Several K-adrenergic receptors also
showed IC50 values on the micromolar range but it was
300^500 times lower than that for the c1 receptor subtype.
This underlines the selectivity of the ligand for c1 receptors.
3.4. E¡ect of BHDP on hypoxia-induced ATP depletion in
cultured astrocytes
Several c receptor agonists and antagonists have been re-
ported to have neuroprotective actions in both in vitro and in
vivo models [18^21]. This led us to study the protective e¡ects
of BHDP against 24 h hypoxia-induced ATP depletion in
cultures of astrocytes. Two degrees of hypoxia were studied.
In a ¢rst series of experiments, a 48% decrease in ATP was
observed following a 24 h hypoxia. BHDP prevented the fall
in ATP levels in a concentration-dependent manner. The pre-
vention was signi¢cant at 1 WM and at 10 WM the protective
e¡ect was complete (Table 3). When a more severe hypoxia
was performed (decrease in ATP level of 62%), the preventing
e¡ect of BHDP still persisted (Table 3).
4. Discussion
This study was undertaken to characterize a novel c recep-
tor ligand, BHDP, in receptor binding studies. This was per-
formed on rat brain synaptosomal membranes and liver mi-
tochondria as we identi¢ed recently the existence of c
receptors on the outer membranes of liver mitochondria [7].
We demonstrated that [3H]BHDP combines both high af-
¢nity and high selectivity for c receptors. [3H]BHDP labelled
one class of high a⁄nity binding sites in liver mitochondria
and in synaptic membranes with similar Kd values of 2^3 nM.
c Reference compounds such as haloperidol, NE-100,
( T )pentazocine, ifenprodil, carbetapentane, ( T )3-PPP exhib-
ited high a⁄nity for [3H]BHDP binding sites, haloperidol
being the most potent. The rank order of potency of these
c reference compounds was identical in the two preparations
and similar to that observed for c1 receptors in previous
studies [3^5].
On the other hand, [3H]BHDP binding was inhibited by
progesterone which is considered as a putative endogenous
ligand for c1 receptors. Taken together, these data suggested
that [3H]BHDP preferentially bound to the c1 receptor sub-
type. This hypothesis was con¢rmed by means of displace-
ment experiments where c1 and c2 receptors were labelled
with [3H](+)-pentazocine and [3H]DTG, respectively. Indeed,
the inhibitory potency of BHDP for the c1 receptor subtype
was about 100 times higher than that for the c2 receptor
subtype.
Numerous drugs were shown to label c receptors but only a
few of them (e.g. SA4503, [11]) display a real selectivity. The
receptor pro¢le of BHDP suggests that this compound has a
similar behavior. Indeed, BHDP did not show any signi¢cant
a⁄nity for a number of receptors, ion channels and trans-
porters tested. Thus, BHDP appears to be a potent and se-
lective c1 receptor ligand in binding experiments.
There is increasing evidence that c receptors represent an
interesting target for neuroprotection since various c receptor
ligands, speci¢cally the c1 subtype, have demonstrated robust
neuroprotective properties in in vitro and animal models of
cerebral ischemia. Several mechanisms have been postulated
to explain their neuroprotective e¡ects and, up today, they
remained controversial. These mechanisms include inhibition
of presynaptic glutamate release [22], bu¡ering of postsynaptic
glutamate-evoked Ca2þ in£ux [23], prevention of the increase
in nitric oxide synthase activity [18,24] and inhibition of do-
pamine release [25]. Given that BHDP demonstrated both
high a⁄nity and selectivity for c1 receptors in binding experi-
ments, we postulated that this drug might possess cytoprotec-
tive properties. Therefore, we tested this hypothesis in a model
of cultured astrocytes subjected to an hypoxia which induced
a severe depletion of ATP. This in vitro test was choosen ¢rst
because ATP level is a good index of the ability of a cell to
recover and secondly because we previously demonstrated the
presence of c receptor in mitochondria [7] which is the major
provider of ATP in the cell. The results indicate that BHDP
prevents ATP depletion in a concentration-dependent manner
and that a complete recovery is obtained at 10 WM. These
results can be compared to those obtained with the c1 recep-
tor agonists (+)-pentazocine and SA4503 which suppressed
hypoxia/hypoglycemia neurotoxicity in rat primary neuronal
cultures [20].
Although the mechanism of action of BHDP cannot be
de¢ned from this particular experiment, these data reinforce
the hypothesis that c ligands are able to mediate cytoprotec-
tive e¡ects through c receptors.
In conclusion, BHDP binds speci¢cally with high a⁄nity to
a single c1 binding site in liver mitochondria and rat brain
membranes. The preventing e¡ect of the drug against hypox-
ia-induced ATP depletion suggests that BHDP is a potential
cytoprotective agent which appears a promising tool to study
c1 receptors located in mitochondrial membranes.
Table 3
E¡ects of BHDP on the decrease in ATP levels in astrocytes main-






+BHDP 0.1 WM 248T20
+BHDP 1 WM 313T32*





+BHDP 0.1 WM 455T33**
+BHDP 1 WM 615T40**
+BHDP 10 WM 1105T 234**
Cultured astrocytes were maintained in hypoxic conditions for 24 h
in the absence or in the presence of increasing concentrations of
BHDP. Then, ATP concentrations were measured by luminescence.
22P6 0.01 versus normoxia.
*P6 0.05 versus hypoxia.
**P6 0.01 versus hypoxia.
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